Roth Capital Predicts Weaker Earnings for Journey Medical

Journey Medical Co. (NASDAQ:DERM) – Research analysts at Roth Capital dropped their Q1 2025 earnings estimates for shares of Journey Medical in a research note issued to investors on Thursday, March 27th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s Q2 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.05 EPS, FY2026 earnings at $2.18 EPS, FY2027 earnings at $3.32 EPS and FY2028 earnings at $5.18 EPS.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.30. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The business had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.21 million.

Separately, Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research report on Thursday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $9.67.

Journey Medical Stock Performance

Shares of NASDAQ DERM opened at $5.90 on Monday. The company’s fifty day moving average price is $5.14 and its 200 day moving average price is $5.18. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical has a 1 year low of $3.20 and a 1 year high of $6.89. The company has a market capitalization of $123.25 million, a PE ratio of -6.28 and a beta of 0.97.

Insider Buying and Selling at Journey Medical

In other Journey Medical news, CEO Claude Maraoui sold 18,147 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total value of $93,094.11. Following the transaction, the chief executive officer now directly owns 2,092,874 shares of the company’s stock, valued at $10,736,443.62. This trade represents a 0.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 105,831 shares of company stock worth $536,622. Corporate insiders own 13.16% of the company’s stock.

Institutional Trading of Journey Medical

Several large investors have recently added to or reduced their stakes in DERM. Cetera Investment Advisers boosted its holdings in Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company’s stock valued at $54,000 after purchasing an additional 2,478 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in shares of Journey Medical in the third quarter valued at $66,000. Dimensional Fund Advisors LP purchased a new stake in Journey Medical during the fourth quarter worth about $80,000. Citadel Advisors LLC purchased a new stake in Journey Medical during the 4th quarter worth approximately $174,000. Finally, Geode Capital Management LLC raised its stake in shares of Journey Medical by 13.5% in the third quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after acquiring an additional 12,882 shares in the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.